Markets

Insider Trading

Hedge Funds

Retirement

Opinion

10 Best Large Cap Stocks to Buy Under $100

In this article, we will discuss the 10 Best Large Cap Stocks to Buy Under $100.

On May 13, Sarat Sethi, DCLA Managing Partner, joined ‘The Exchange’ on CNBC to discuss a notable shift in market sentiment and the emerging opportunities in the software sector. He observed that many investors and traders are moving away from well-capitalized, high-quality companies in favor of quick trades in semiconductors and DRAM names, which he views as more speculative commodity plays. Sethi emphasized that as a long-term, value-oriented compounder investor, he finds the current valuation of software companies particularly attractive. He pointed out that software, which traded at 20x cash flow just a year ago, is now trading at 10x to 12x cash flow, despite maintaining 8% to 10% earnings growth and carrying almost no debt.

Sethi argued that there is an underappreciated synergy between hardware and software, noting that semiconductors will ultimately need software to function effectively. He dismissed fears that software companies are being left behind by AI, asserting that they are actively using the tech and engineers to enhance their products. Sethi also stressed the continued necessity of cybersecurity and interoperability, though he cautioned that investors must remain selective. He believes that it is vital to distinguish between companies with forward-looking management and those that may stagnate and see their cash flows slowly decline. Regarding semiconductors, Sethi expresses caution despite holding exposure in that area. He concluded by noting that the high correlation of semiconductor stocks in ETFs and the current market froth give him pause as a long-term investor, suggesting that the sector may be overheating.

Our Methodology

We used screeners to identify stocks with market caps between $10 billion and $200 billion and a share price below $100. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q4 2025.

Note: All data was sourced on May 14. 

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

10 Best Large Cap Stocks to Buy Under $100

10. ​Arch Capital Group Ltd. (NASDAQ:ACGL)

Number of Hedge Fund Holders: 51

​Arch Capital Group Ltd. (NASDAQ:ACGL) is one of the best large cap stocks to buy under $100. On April 28, Arch Capital Group announced a strong start to 2026, reporting net income available to common shareholders of $1.0 billion, or $2.88 per share. This performance marks a significant increase from the $564 million reported in Q1 2025. The company achieved an annualized operating return on average common equity of 15.4%, supported by $901 million in after-tax operating income.

The company’s underwriting results featured a consolidated combined ratio of 81.7%, an improvement over the 90.1% seen in the prior year’s Q1. These results were supported by $200 million in favorable development from prior year loss reserves and a reduction in catastrophic losses, which totaled $174 million compared to higher levels in 2025. While gross premiums written remained relatively stable at $6.4 billion, underwriting income saw a substantial 74.6% increase to $728 million.

In terms of capital management and financial position, ​Arch Capital Group Ltd. (NASDAQ:ACGL) repurchased $783 million of its common shares during the quarter. Book value per common share rose to $66.19 as of March 31, representing a 1.7% increase from the end of 2025. CEO Nicolas Papadopoulo attributed the successful quarter to a disciplined approach to underwriting and capital allocation, noting that the company’s strong balance sheet continues to position it for best-in-class returns.

​Arch Capital Group Ltd. (NASDAQ:ACGL) is an insurance and reinsurance company that provides property, casualty, and mortgage insurance solutions worldwide. The firm operates through 3 segments: Insurance, Reinsurance, and Mortgage, with a strong presence in the US, Europe, and Bermuda.

9. Ventas Inc. (NYSE:VTR)

Number of Hedge Fund Holders: 53

Ventas Inc. (NYSE:VTR) is one of the best large cap stocks to buy under $100. On April 27, Ventas reported strong financial results for Q1 2026, driven primarily by organic growth in its senior housing operating portfolio/SHOP. The company achieved net income attributable to common stockholders of $0.11 per share and Normalized Funds From Operations/FFO of $0.94 per share, a 9% increase compared to the same period in the prior year. Total company net operating income/NOI grew 14% year-over-year, while total same-store cash NOI rose by 9%.

The company’s SHOP segment served as the primary performance driver, delivering a same-store cash NOI increase of more than 15% year-over-year. This growth was supported by a 9% rise in same-store cash operating revenues, 170 basis points of NOI margin expansion, and a 310 basis point improvement in average occupancy. Driven by this positive momentum and a robust pipeline, Ventas raised its 2026 investment volume expectations to $3.0 billion, having already closed $1.7 billion in senior housing investments year-to-date through April.

Backed by strong property performance and recent investment accretion, Ventas Inc. (NYSE:VTR) increased its full-year 2026 guidance, projecting a revised Normalized FFO per share midpoint of $3.86 and an attributable net income per share midpoint of $0.60. The company also enhanced its financial flexibility by strengthening its net debt-to-further adjusted EBITDA ratio to 5.0x, marking its tenth consecutive quarter of sequential improvement.

Ventas Inc. (NYSE:VTR) is a healthcare-focused REIT that owns a portfolio of properties, including senior housing communities, outpatient medical buildings, research centers, hospitals, and other healthcare facilities. The company owns around 1,400 properties across North America and the UK.

8. Crown Castle Inc. (NYSE:CCI)

Number of Hedge Fund Holders: 55

Crown Castle Inc. (NYSE:CCI) is one of the best large cap stocks to buy under $100. On April 22, Crown Castle reported its financial results for Q1 2026, delivering a net income of $151 million, or $0.34 per diluted share, compared to a net loss of $464 million in Q1 2025. This recovery was driven by a reduced impact from losses associated with the pending sale of its Fiber Business. However, site rental revenues fell 5% year-over-year to $961 million, impacted by contract terminations and cancellations from DISH and Sprint, as well as decreases in straight-lined revenues and prepaid rent amortization.

Operationally, the company is progressing toward its transition into a pure-play tower business, with the separation of its Fiber and Small Cell segments largely finalized and the sale anticipated to close in H1 2026. Following the closure, Crown Castle plans to deploy the proceeds to repurchase ~$1 billion in shares and repay ~$7 billion in debt, which is expected to lower annual interest expenses by $120 million.

Crown Castle Inc. (NYSE:CCI) maintained its full-year 2026 outlook, projecting site rental revenues between $3.83 billion and $3.87 billion, net income of $640 million to $920 million, and an AFFO per share range of $4.38 to $4.49. The full-year guidance accounts for a $240 million headwind from the DISH and Sprint cancellations, which will be partially mitigated by an anticipated $55 million in cost savings from a restructuring plan that downsized its tower and corporate workforce.

Crown Castle Inc. (NYSE:CCI) is a Houston-based real estate investment trust (REIT) owning and operating communications infrastructure.

7. Microchip Technology Inc. (NASDAQ:MCHP)

Number of Hedge Fund Holders: 61

Microchip Technology Inc. (NASDAQ:MCHP) is one of the best large cap stocks to buy under $100. On May 7, Microchip reported FQ4 2026 net sales of $1.311 billion, up 35.1% year-over-year, with GAAP EPS of $0.21 and non-GAAP EPS of $0.57, exceeding previous guidance. For the full fiscal year 2026, net sales rose 7.1% to $4.713 billion, generating GAAP net income of $118.8 million ($0.22 per diluted share) and non-GAAP net income of $933.9 million ($1.64 per diluted share).

The company successfully executed its recovery plan, returning $984.0 million to shareholders through dividends and reducing inventory by $320.9 million from its peak in late 2024 to bring days of inventory down to 185 days. Driven by improving demand conditions, normalizing customer inventory, and design wins in data center and AI applications, factory utilization is being increased to capture growing operating leverage.

For FQ1 2027, Microchip Technology Inc. (NASDAQ:MCHP) expects strong momentum to continue, forecasting a net sales midpoint of $1.456 billion, which represents an 11% sequential increase. Q1 non-GAAP gross margins are projected between 62.25% and 63.25%, with non-GAAP EPS expected to rise to a range of $0.67 to $0.71, while full-year capital expenditures will be managed at ~$100 million.

Microchip Technology Inc. (NASDAQ:MCHP) provides smart, connected, and secure embedded control solutions. Its semiconductor products business designs, develops, manufactures, and markets mixed-signal microcontrollers, development tools, analog and interface products, timing and connectivity devices, and memory products.

6. Guardant Health Inc. (NASDAQ:GH)

Number of Hedge Fund Holders: 62

Guardant Health Inc. (NASDAQ:GH) is one of the best large cap stocks to buy under $100. On May 7, Guardant Health reported Q1 2026 total revenue of $301.7 million, a 48% increase year-over-year driven by strong performance across its portfolio. Oncology revenue grew 36% to $205.0 million, Biopharma & Data revenue rose 17% to $53.0 million, and Screening revenue surged over 600% to $41.6 million. The company achieved a GAAP gross margin of 65% and a non-GAAP gross margin of 66%.

Operating expenses rose due to commercial infrastructure expansion and marketing, resulting in a GAAP net loss of $112.1 million ($0.85 per share) and a non-GAAP net loss of $58.7 million ($0.45 per share). The adjusted EBITDA loss was $58.9 million, while free cash flow stood at negative $71.2 million. Guardant Health Inc. (NASDAQ:GH) closed the quarter with $1.2 billion in cash, cash equivalents, restricted cash, and marketable securities.

Key operational milestones included expanding Guardant360 Tissue capabilities, securing FDA companion diagnostic approval for Guardant360 CDx, and partnering with Quest and Manulife. Driven by this momentum, the company raised its full-year 2026 revenue guidance to a range of $1.30 to $1.32 billion, representing 32% to 34% growth over the prior year.

Guardant Health Inc. (NASDAQ:GH) is a precision oncology firm.

While we acknowledge the potential of GH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GH and that has 100x upside potential, check out our report about the cheapest AI stock.

Click to continue reading and see the 5 Best Large Cap Stocks to Buy Under $100.

Disclosure: None. None. Follow Insider Monkey on Google News.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.